Zika screening tool for pregnant women by Centers for Disease Control and Prevention (U.S.)
Note: On May 5, 2017, CDC issued a Health Alert Notice (HAN) (https://emergency.cdc.gov/han/han00402.asp) to 
share emerging evidence about interpreting Zika IgM antibody test results of women who may have been exposed to 
Zika virus, particularly women who live in or frequently travel to areas with a CDC Zika travel notice, before 
conception. It is possible that some women who are currently pregnant may have been previously infected and 
developed antibodies against Zika prior to pregnancy. New data suggest that Zika virus infection, similar to some other 
flavivirus infections, may result in Zika antibodies staying in the body for months after infection, which may make it 
difficult to use these tests to determine whether women might have been infected before or after they became 
pregnant. This HAN has specific recommendations not currently a part of the existing laboratory guidance, which 
should be considered for these women: 1. that nucleic acid testing is considered at least once per trimester unless a 
previous test has been positive, and on amniocentesis specimens, if amniocentesis is performed for other reasons and 
2. that IgM testing may be considered as part of pre-conception counseling. CDC recommends other diagnostic
methods, such as nucleic acid testing and ultrasounds, which may provide additional information to help healthcare
providers know if antibody test results might represent a recent infection. CDC is currently updating its webpages with
this information.
CDC’s Response to Zika
ZIKA SCREENING TOOL FOR PREGNANT WOMEN
(To be administered by nurse or other healthcare provider)
All pregnant women should be assessed for possible Zika virus exposure at each prenatal care visit. Use this tool to evaluate pregnant women for exposure to Zika virus and for signs 
and symptoms of Zika virus disease to determine whether testing is indicated. 




to see an 
updated map 
of areas with 
risk of Zika1: 
Assess the patient for 
exposure to an area with 
risk of Zika2 or having 
a sex partner with such 
exposure by asking: 
www.cdc.gov/zika/geo/
countries-territories.html
This page shows areas  
with a CDC Zika travel 
notice as well as areas with 
risk of Zika but no CDC 
travel notice. Check the 
map often to keep up to 
date with changes to the 
travel notices. 
1. Have you lived in one 
of these areas during 
pregnancy or up to 6 
weeks before your last 
menstrual period?
2. Have you traveled to one 
of these areas during 
pregnancy or up to 6 
weeks before your last 
menstrual period?  
3. During pregnancy, have 
you had unprotected sex 
with a partner who lived 
in or traveled to one of 
these areas?    
If the patient answered yes to any of the questions regarding exposure 
to an area with a CDC Zika travel notice, she should be tested in 
accordance with CDC guidance for pregnant women (reverse).
Patients who answered “NO” to ALL questions are at low risk for exposure 
to Zika virus infection. 
If the patient has been exposed to an area with risk of Zika but no CDC 
Zika travel notice, assess the patient for possible Zika virus infection. 
Does the patient 
1. Currently have or had (in the last 12 weeks) fever, rash,  
joint pain, muscle pain, headache, or red eyes? 
2. Have evidence of abnormalities consistent with Zika been  
seen on ultrasound?  
If “Yes” to either question, test in accordance with CDC guidance for 
pregnant women.
If “No” to both questions, Zika testing is not routinely recommended for 
asymptomatic pregnant women exposed to areas without a CDC travel 
notice but can be offered on case-by-case basis.
Footnotes:
1. Area with risk of Zika in the US refers to Zika cautionary areas and Zika active transmission areas. 
2. For patients with exposure to areas with a CDC Zika travel notice AND areas with risk of Zika but no 








CDC’s Response to Zika
Testing and interpretation recommendations*,†, §,¶ for a pregnant woman with possible exposure to Zika virus** — United States (including U.S. territories)
PREGNANT WOMAN
Assess for possible Zika virus exposure
Evaluate for signs and symptoms of Zika virus diseaseA
• Symptomatic : <2 weeks after symptom onset, or
• Asymptomatic and NOT living in an area with active Zika 
virus transmission: <2 weeks after possible exposure
Zika virus NAT on serum and urine
Positive Zika virus NAT on serum or urine:
Recent Zika virus infection
Negative Zika virus NAT on serum and urine
• Symptomatic: Zika virus IgM and dengue virus IgM
• Asymptomatic and NOT living in an area with active Zika virus 
transmission: Zika virus IgM 2–12 weeks after exposure 
Zika virus IgM and dengue virus IgM negative: 
No recent Zika virus infection
Zika virus IgM or dengue virus IgM positive or equivocal 
Presumptive recent Zika virus or dengue virus or flavivirus infection
Plaque reduction neutralization test (PRNT)
Zika virus PRNT ≥10 and dengue virus PRNT <10:
Recent Zika virus Infection
Zika virus PRNT ≥10 and dengue virus PRNT ≥10: 
Recent flavivirus infection, specific virus cannot be identified
Zika virus PRNT <10:
No recent evidence of Zika virus infection
B 
• Symptomatic: 2–12 weeks after symptom onset, or
• Asymptomatic and NOT living in an area with active Zika virus transmission: 
2–12 weeks after possible exposure, or
• Asymptomatic and living in an area with active Zika virus transmission: 
1st and 2nd trimester 
Zika virus IgM and dengue virus IgM§ on serum
Dengue virus IgM 
positive or equivocal and 
Zika virus IgM negative:
Presumptive dengue 
virus infection 
Zika virus IgM positive or equivocal 
and  any result on dengue virus IgM:
Presumptive recent Zika virus or 
flavivirus infection 
Zika virus IgM and dengue 
virus IgM negative: 
No recent Zika virus 
infection
Reflex Zika virus NAT on serum and urine
Negative Zika virus NAT on serum Positive Zika virus NAT on serum or urine: 
Recent Zika virus infection
Abbreviations: IgM = immunoglobulin M; PRNT = plaque reduction neutralization test; NAT = nucleic acid testing. 
* A pregnant woman is considered symptomatic if one or more signs or symptoms (fever, rash, arthralgia, 
or conjunctivitis) consistent with Zika virus disease is reported whereas a pregnant woman is considered 
asymptomatic if symptoms are NOT reported.
† Testing includes Zika virus NAT on serum and urine samples, Zika virus and dengue virus Immunoglobulin M (IgM), 
and plaque reduction neutralization test (PRNT) on serum samples. PRNT results that indicate recent flavivirus 
infection should be interpreted in the context of the currently circulating flaviviruses. Refer to the laboratory 
guidance for updated testing recommendations (http://www.cdc.gov/zika/laboratories/lab-guidance.html). 
Because of the overlap of symptoms in areas where other viral illness are endemic, evaluate for possible dengue 
or chikungunya virus infection.
§ Dengue IgM antibody testing is recommended only for symptomatic pregnant women.
¶ If Zika virus NAT testing is requested from laboratories without IgM antibody testing capacity or a process to 
forward specimens to another testing laboratory, storing of additional serum samples is recommended for IgM 
antibody testing in the event of a NAT negative result.
** Possible exposure to Zika virus includes travel to or residence in an area with active Zika virus transmission 
(http://wwwnc.cdc.gov/travel/notices/), or sex (vaginal sex (penis-to-vagina sex), anal sex (penis-to-anus sex), oral 
sex (mouth-to-penis sex or mouth-to-vagina sex), and the sharing of sex toys) without a barrier method to prevent 
infection (male or female condoms for vaginal or anal sex, male condoms for oral sex (mouth-to-penis), and male 
condoms cut to create a flat barrier or dental dams for oral sex (mouth-to-vagina) with a partner who traveled to, 
or lives in an area with active Zika virus transmission.
